UPDATE | October 4, 2023

S-DUAL™: A novel bispecific antibody scaffold with higher heterodimer formation

  • MAIL

Posters - S-DUAL™: A novel bispecific antibody scaffold with higher heterodimer formation 

Here we report the development of S-DUAL™ , Samsung Biologics’ BsAb Platform with a novel asymmetrical structure that delivers a 99% HC-LC-pairing success rate. The platform’s unique asymmetric design enables the seamless addition of complementarity-determining regions (CDRs) of interest without additional engineering processes, while maintaining high binding affinity and productivity.


Posters - S-DUAL™: A novel bispecific antibody scaffold with higher heterodimer formation 

Here we report the development of S-DUAL™ , Samsung Biologics’ BsAb Platform with a novel asymmetrical structure that delivers a 99% HC-LC-pairing success rate. The platform’s unique asymmetric design enables the seamless addition of complementarity-determining regions (CDRs) of interest without additional engineering processes, while maintaining high binding affinity and productivity.


  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required